News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Sarepta Therapeutics, Inc.
NEWS
JOBS
IN THE PRESS
NEWS
FDA
Meet the Powerful Woman Behind the Scenes of Sarepta’s DMD Drug Approval
September 20, 2016
·
4 min read
FDA
Victory at Last! Sarepta Stock Doubles as the FDA Finally Approves DMD Drug
September 19, 2016
·
3 min read
Business
Turn the Page: Sarepta Stock Pops on Rumors DMD Drug Naysayer Leaves the FDA
September 14, 2016
·
3 min read
Biotech Beach
3 High-Risk, High-Reward Biotech Stocks
August 24, 2016
·
3 min read
Policy
Sarepta’s Duchene Muscular Dystrophy Drug: Evaluating the Placebo Effect
August 19, 2016
·
4 min read
Drug Development
Sarepta Stock Surges After Government Website Indicates Firm is Recruiting for Phase III Study
August 4, 2016
·
3 min read
Policy
Sarepta Surges Yet Again, as the FDA Requests More Data About Duchenne’s Drug
June 7, 2016
·
3 min read
Policy
All Eyes Turn to Sarepta as BioMarin Shutters Its Kyndrisa Duchenne Program
June 1, 2016
·
4 min read
Policy
Approving Sarepta’s DMD Drug Could Force FDA To Get Creative
May 26, 2016
·
1 min read
AWARDS
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Genetown
Sarepta Therapeutics Reports Sustained Functional Improvement Two Years After Treatment with SRP-9001, its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
September 28, 2020
·
7 min read
Genetown
Sarepta Therapeutics Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Functional Improvements 18-months After Administration
September 28, 2020
·
8 min read
Genetown
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program
September 15, 2020
·
3 min read
Genetown
Long-term functional data from Sarepta Therapeutics’ Most Advanced Gene Therapy Programs to be Presented at Upcoming Annual Congress of the World Muscle Society
September 14, 2020
·
4 min read
Genetown
Sarepta Therapeutics Provides Program Update for SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
September 9, 2020
·
5 min read
Genetown
Sarepta Therapeutics to Present at Upcoming Investor Conferences - Sep 03, 2020
September 3, 2020
·
1 min read
Deals
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 31, 2020
August 31, 2020
·
2 min read
Genetown
Sarepta Therapeutics Announces FDA Acceptance of Casimersen (SRP-4045) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45
August 25, 2020
·
10 min read
Business
Sarepta Therapeutics and University of Florida Announce Collaboration to Accelerate the Discovery and Development of Therapies for Rare Genetic Diseases
August 11, 2020
·
6 min read
Business
Sarepta Therapeutics Announces Second Quarter 2020 Financial Results and Recent Corporate Developments
August 5, 2020
·
30 min read
